Ipamorelin: Research, Mechanism of Action & Scientific Overview

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide (five amino acids) originally developed by Novo Nordisk as part of a class of compounds known as growth hormone-releasing peptides (GHRPs). It acts as an agonist at the growth hormone secretagogue receptor (GHSR-1a), the same receptor targeted by the endogenous hormone ghrelin, to stimulate the pulsatile release of growth hormone from the anterior pituitary gland.

What distinguishes Ipamorelin within the GHRP family is its selectivity. Earlier GHRPs such as GHRP-2 and GHRP-6 have been shown to also stimulate the release of cortisol, prolactin, and ACTH at therapeutic research doses. Ipamorelin, by contrast, has demonstrated a highly selective GH response in preclinical and clinical studies, with minimal impact on these other hormonal axes.

Key Identifier

Peptide Profile

Full Name: Ipamorelin
Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2
Molecular Weight: ~711.86 Da
Amino Acid Residues: 5 (pentapeptide)
Classification: GHRP, Ghrelin receptor agonist, GH secretagogue
Developer: Novo Nordisk

Mechanism of Action

Ipamorelin exerts its effects through activation of the ghrelin/GH secretagogue receptor (GHSR-1a) and works complementarily, not redundantly, with the native GHRH pathway. Understanding this dual-pathway interaction is central to its research profile.

Ghrelin Receptor Agonism

Ipamorelin binds to the growth hormone secretagogue receptor (GHSR-1a) on somatotroph cells in the anterior pituitary. This receptor is the same one activated by endogenous ghrelin, the hormone produced primarily in the stomach. Receptor binding triggers a G-protein coupled signaling cascade that results in the release of stored growth hormone into systemic circulation.

Selective GH Release

A defining characteristic of Ipamorelin is its selectivity. Preclinical and clinical investigations have demonstrated that Ipamorelin stimulates growth hormone release with minimal or no measurable elevation in cortisol, prolactin, ACTH, LH, FSH, or TSH. This stands in contrast to earlier-generation GHRPs such as GHRP-2 and GHRP-6, which were shown to elevate stress and stimulatory hormones alongside GH, making Ipamorelin one of the cleanest secretagogues studied.

Synergy with GHRH Analogs

Because Ipamorelin acts on the ghrelin receptor while GHRH analogs (such as CJC-1295 or Sermorelin) act on the GHRH receptor, the two pathways converge on the somatotroph to produce an additive, and in some studies, synergistic, increase in GH release. This pathway complementarity is why Ipamorelin is frequently studied in combination research protocols.

Preservation of Pulsatile Release

Ipamorelin stimulates GH in a pulsatile pattern consistent with the body's endogenous secretion rhythm. Unlike exogenous recombinant GH, which bypasses the hypothalamic-pituitary axis entirely and can suppress natural GH production through negative feedback, Ipamorelin works upstream of the pituitary and preserves feedback regulation, including somatostatin control.

Research Overview

Ipamorelin has been evaluated across preclinical and clinical studies examining GH selectivity, body composition, recovery, and gastrointestinal motility. The following table summarizes key areas of investigation.

Research Area	Key Findings	Study Type
GH Selectivity	Studies demonstrate robust GH release with minimal to no elevation of cortisol, prolactin, or ACTH	In vivo (human/rodent)
IGF-1 Response	Research indicates downstream elevation of insulin-like growth factor-1 (IGF-1) following repeated GH pulses	In vivo (human/rodent)
Body Composition	Preclinical studies have investigated effects on lean mass accretion and fat mass modulation	In vivo
Bone Mineral Density	Animal research has examined effects on bone formation markers and mineral density	In vivo (rodent)
Gastrointestinal Motility	Clinical investigation has explored Ipamorelin's potential role in postoperative ileus resolution	In vivo (human)
GHRH Synergy	Studies have examined combined administration with GHRH analogs demonstrating additive GH release	In vivo

Research Context

Ipamorelin has been studied in both rodent and human models. Published research has focused on its hormonal selectivity profile, GH kinetics, body composition, bone biology, and synergy with GHRH analogs. A Phase 2b clinical trial (2013) also evaluated Ipamorelin for postoperative ileus resolution, providing human safety and pharmacokinetic data.

Common Areas of Research Interest

Scientific interest in Ipamorelin centers on its selectivity and clean hormonal profile, making it a frequent subject in research domains where off-target hormonal effects are undesirable.

Selective GH stimulation, Ipamorelin is studied as a tool for isolating GH effects without confounding elevations in cortisol or prolactin
Body composition, Preclinical research has investigated effects on lean mass preservation and fat mass modulation
Recovery and tissue repair, Studies have examined GH-mediated recovery pathways relevant to musculoskeletal research
Bone metabolism, Animal models have evaluated Ipamorelin's effects on bone formation markers and density
Combination protocols, Research frequently pairs Ipamorelin with GHRH analogs (e.g., CJC-1295, Sermorelin) to study additive GH release
Age-related GH decline, Investigations have examined Ipamorelin in models of somatopause and age-related GH axis decline

Pharmacokinetics

Understanding the pharmacokinetic profile of Ipamorelin is essential for contextualizing its biological activity and research applications. The following parameters summarize key pharmacokinetic characteristics observed in the literature.

~2 hrs

Half-Life

711.86

Molecular Weight (Da)

Amino Acid Residues

Administration Route

Ipamorelin has a half-life of approximately two hours, longer than earlier GHRPs such as GHRP-6 (~15–30 minutes) and considerably longer than native ghrelin, supporting a more sustained GH secretagogue effect per dose. As a small pentapeptide (~712 Da), it is generally administered via subcutaneous injection in research settings. Its short chain length and simplified structure contribute to relatively high chemical stability compared to larger peptide analogs.

Comparison to Similar Peptides

Ipamorelin sits within a broader family of growth hormone secretagogues and GHRH analogs. The following comparison highlights key distinctions among these compounds.

Feature	Ipamorelin	GHRP-6	GHRP-2	CJC-1295 (No DAC)	Sermorelin
Classification	GHRP / Ghrelin agonist	GHRP / Ghrelin agonist	GHRP / Ghrelin agonist	GHRH analog	GHRH analog (1-29)
Amino Acids	5	6	6	29 (modified)	29
Half-Life	~2 hours	~15–30 min	~15–60 min	~30 min	~10 min
Receptor	GHSR-1a	GHSR-1a	GHSR-1a	GHRH receptor	GHRH receptor
Cortisol/Prolactin	Minimal effect	Elevates	Elevates	Minimal effect	Minimal effect
Hunger Stimulation	Minimal	Marked	Moderate	None	None

Frequently Asked Questions

What is Ipamorelin and where does it come from?

Ipamorelin is a synthetic pentapeptide originally developed by Novo Nordisk as a selective growth hormone secretagogue. It belongs to the class of compounds known as growth hormone-releasing peptides (GHRPs) and acts as an agonist at the ghrelin/GH secretagogue receptor (GHSR-1a) to stimulate pulsatile GH release from the anterior pituitary.

How is Ipamorelin different from other GHRPs like GHRP-2 or GHRP-6?

The primary distinction is selectivity. GHRP-2 and GHRP-6 have been shown in research to elevate cortisol, prolactin, and ACTH alongside GH, and GHRP-6 is well known for strongly stimulating hunger. Ipamorelin has consistently demonstrated a much cleaner profile, robust GH release with minimal to no effect on these off-target hormonal pathways. This makes it a preferred research compound when hormonal specificity matters.

How does Ipamorelin differ from exogenous growth hormone?

Ipamorelin stimulates the body's endogenous GH production by signaling the pituitary through the ghrelin receptor pathway. In contrast, recombinant growth hormone replaces GH directly and can suppress the body's own production through negative feedback. Because Ipamorelin works upstream of the pituitary, it preserves natural regulatory mechanisms, including somatostatin feedback, so the GH axis continues to function physiologically.

Why is Ipamorelin commonly studied with CJC-1295?

Ipamorelin and CJC-1295 act on two different receptors: Ipamorelin binds the ghrelin receptor (GHSR-1a) while CJC-1295 binds the GHRH receptor. Because these pathways converge on the same pituitary somatotrophs, their combined administration produces an additive, and in some studies, synergistic. GH release. This complementarity is the basis for the frequent pairing of the two peptides in research protocols.

Does Ipamorelin stimulate appetite like GHRP-6?

Research suggests Ipamorelin has minimal impact on appetite compared to GHRP-6, which binds the same receptor but produces pronounced hunger signaling. While Ipamorelin activates the ghrelin receptor on pituitary somatotrophs, it appears to have limited effect on central ghrelin-mediated feeding behavior at GH-stimulating doses. This is one of the reasons it is regarded as a cleaner research tool than earlier GHRPs.

What does the research show about Ipamorelin?

Published research on Ipamorelin spans rodent and human studies. Findings consistently demonstrate dose-dependent, selective GH release with minimal cortisol/prolactin elevation, downstream IGF-1 responses, and potential effects on body composition and bone formation markers. Human clinical research has also evaluated Ipamorelin for gastrointestinal motility in the postoperative ileus setting. Findings are available through PubMed and peer-reviewed journals.

Sources & References

Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology. 1998;139(5):552-561. PubMed
Gobburu JVS, et al. "Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide." Journal of Pharmacology and Experimental Therapeutics. 1999;288(2):551-558. PubMed
Svensson J, et al. "The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats." Journal of Endocrinology. 2000;165(3):569-577. PubMed
Johansen PB, et al. "Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats." Growth Hormone & IGF Research. 1999;9(2):106-113. PubMed
Beck DE, et al. "Safety and efficacy of ipamorelin for the management of postoperative ileus." Annals of Surgery. 2014;259(2):346-354. PubMed
Ghigo E, et al. "Ghrelin and growth hormone-releasing peptides: Biological role and therapeutic perspectives." Endocrine Reviews. 2018;39(3):236-287. PubMed
Sinha DK, et al. "Beyond the androgen receptor II: new approaches to understanding and treating osteoporosis." Translational Andrology and Urology. 2020;9(Suppl 2):S160-S172. PubMed
Sigalos JT, Pastuszak AW. "The safety and efficacy of growth hormone secretagogues." Sexual Medicine Reviews. 2018;6(1):45-53. PubMed

Explore Ipamorelin 10mg

Available for research purposes. Third-party tested for purity and identity.

View Ipamorelin — $55

This product is intended for research and laboratory use only. It is not intended for human consumption.

Disclaimer: This content is provided for educational and informational purposes only. It is not intended as medical advice, nor does it constitute a recommendation for the treatment, cure, or prevention of any disease or condition. Ipamorelin is sold for research purposes only and is not intended for human consumption. Always consult a qualified healthcare professional before making decisions about your health. Somata Peptides does not claim that any products treat, cure, or prevent any disease.